Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 7, 2011, Pages 2106-2112

  Garofalo, Antonio ^a,b   Goossens, Laurence ^a,b   Six, Perrine ^a,b   Lemoine, Amélie ^a,b   Ravez, Séverine ^a,b   Farce, Amaury ^a   Depreux, Patrick ^a,b  

^a UNIV LILLE   (France)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

Author keywords

Anticancer agents; EGFR; Quinazoline; RTK inhibitors; VEGFR2

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANILINOQUINAZOLINE DERIVATIVE; BEVACIZUMAB; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; QUINAZOLINE DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; KIDNEY CARCINOMA; PHARMACOPHORE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 79952489958     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.137     Document Type: Article

References (34)

1. Levitzki, A. Acc. Chem. Res. 2003, 36, 462.
2. Cohen, P. Nat. Rev. Drug Disc. 2002, 1, 309.
3. Cohen, P. Eur. J. Biochem. 2001, 268, 5001.
4. Zwick, E.; Bange, J.; Ullrich, A. Trends Mol. Med. 2002, 8, 17.
5. Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Med. Res. Rev. 2001, 21, 499.
6. Lohela, M.; Bry, M.; Tammela, T.; Alitalo, K. Curr. Opin. Cell Biol. 2009, 21, 154-165.
7. Rahimi, N. Exp. Eye Res. 2006, 83, 1005.
8. Roskoski, R., Jr. Biochem. Biophys. Res. Commun. 2004, 319, 1.
9. Carmeliet, P. Nat. Med. 2003, 9, 653.
10. Pandya, N. M.; Dhalla, N. S.; Santani, D. D. Vasc. Pharmacol. 2006, 44, 265.
11. Otrock, Z. K.; Mahfouz, R. A. R.; Makarem, J. A.; Shamseddine, A. I. Blood Cell Mol. Dis. 2007, 39, 212.
12. Roskoski, R., Jr. Biochem. Biophys. Res. Commun. 2008, 375, 287.
13. Roskoski, R., Jr. Crit. Rev. Oncol. Hematol. 2007, 62, 179.
14. Fayette, J.; Soria, J. C.; Armand, J. P. Eur. Cancer Res. 2005, 41, 1109.
15. Sun, S.; Schiller, J. H. Crit. Rev. Oncol. Hematol. 2007, 62, 93.
16. Denny, W. A. Il Farmaco 2001, 56, 51.
17. Fry, D. W. Exp. Cell Res. 2003, 284, 131.
18. Bridges, A. J.; Zhou, H.; Cody, D.; Rewcastle, G. W.; Mc-Michael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. J. Med. Chem. 1996, 39, 267.
19. Garofalo, A.; Goossens, L.; Baldeyrou, B.; Lemoine, A.; Ravez, S.; Six, P.; David-Coordonnier, M. H.; Bonte, J. P.; Depreux, P.; Lansiaux, A.; Goossens, J. F. J. Med. Chem. 2010, 53, 8089.
20. Ranson, M.; Wardell, S. J. Clin. Pharm. Ther. 2004, 29, 95.
21. Shepherd, F. A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L. N. Eng. J. Med. 2005, 353, 123.
22. Nelson, M. H.; Dolder, C. R. Ann. Pharmacother. 2006, 40, 261.
23. Ciardiello, F.; Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A. R.; Tortora, G. Clin. Cancer Res. 2004, 10, 784.
24. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. N. Eng. J. Med. 2009, 49, 332.
25. Garofalo, A.; Goossens, L.; Lemoine, A.; Farce, A.; Arlot, Y.; Depreux, P. J. Enzyme Inhib. Med. Chem. 2010, 25, 158.
26. Dent, P.; Curiel, D. T.; Fisher, P. B.; Grant, S. Drug Resist. Update 2009, 12, 65.
27. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jürgensmeier, J. M.; Ogilvie, D. J. Cancer Res. 2005, 15, 389.
28. Garofalo, A.; Goossens, L.; Lemoine, A.; Ravez, S.; Six, P.; Howsam, M.; Farce, A.; Depreux, P. MedChemComm 2011, 2, 65.
29. Furuta, T.; Sakai, T.; Senga, T.; Osawa, T.; Kubo, K.; Shimizu, T.; Suzuki, R.; Yoshino, T.; Endo, M.; Miwa, A. J. Med. Chem. 2006, 49, 2186.
30. Garofalo, A.; Goossens, L.; Lebegue, N.; Depreux, P. Synthetic Commun., in press.
31. Gibson, K. H.; Grundy, W.; Godfrey, A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Bioorg. Med. Chem. Lett. 1997, 7, 2723.
32. 32P]ATP 0.5 μCi). The reaction was stopped by adding 20 μL of trichloroacetic acid 100%. Wells were screened out and washed 10 times with trichloroacetic acid 10%. Plates were counted in a Top Count for 1 min per well.
33. +)-tr (min): 3.43.
34. Molecular modeling: All the calculations have been carried out under the Sybyl 6.9.1 molecular modeling package running on Silicon Graphics Octane 2 workstations. The ligands were built from the internal fragments library of Sybyl and their geometry was optimized by the Powell method available in the Maximin2 procedure to a gradient of 0.001 Kcal/mol Å. The dielectric constant was set to 4 to implicitly represent a biological medium the atomic charges were attributed following the Gasteiger-Hückel method and the energy minimization was run with the Tripos force field. The structure of the protein co-crystallized with an inhibitor was obtained from the Protein Data Bank (http://www.pdb.org) under the entry 1YWN.